Tobii Technology AB, the global leader in eye tracking technology, is well-established in a number of high-value niche markets, such as scientific analysis, market research, website usability analysis and in helping those with certain physical disabilities to communicate better with computer-based assistive technology devices. The company is also poised to enter several more markets. Embedding eye tracking systems onto computer chips allows Tobii to offer the only generic end-to-end plug-and-play system available commercially today.

Amadeus was attracted to Tobii because of its established track record in launching new products profitably and because of the opportunity to leverage a common technology platform in new markets, such as anti-drowsiness indicators for drivers, medical diagnostics for glaucoma and other eye-related conditions, and security access control.

Amadeus and Northzone Capital led a €16 million Series B round financing in Tobii, which is based in Stockholm with eight international offices. Investor Growth Capital, an existing Tobii investor, also participated in this round. The financing will be used for business development, and research and development into new applications and markets. Jeppe Zink is a non-executive director on the Board of Tobii.